Navigation Links
Ontario Institute for Cancer Research Validates NEBNext(TM) DNA Sample Preparation Reagents from New England Biolabs for use in Next Generation Sequencing

IPSWICH, Mass., Sept. 29 /PRNewswire/ -- Dr. John McPherson, Platform Leader, Cancer Genomics and High-Throughput Screening, and Dr. Kamran Shazand, Project Manager, of the Ontario Institute for Cancer Research (OICR) led a team of scientists who have completed a thorough evaluation of the NEBNext(TM) DNA Sample Prep Reagents for use with OICR's Illumina® Genome Analyzer II. Dr. McPherson said of the evaluation, "We are constantly striving for the best quality sequencing results at a price that does not restrict our throughput needs and NEB's new reagents meet this need well."

(Logo: )

"We are extremely pleased that OICR, as a world leading genome center, has determined that our reagents meet their high standards," stated Dr. Peter Nathan, Director of Global Business Development at New England Biolabs.

NEBNext(TM) DNA Sample Prep Reagent Sets contain enzymes and buffers that are ideally suited for sample preparation for next generation sequencing, and for preparation of expression libraries. Reagents are available for each step of the library construction workflow, including end repair, dA-tailing, adapter ligation and amplification. These sets are highly cost effective and each of the components must pass rigorous quality control and validation, including independent third-party evaluation on the appropriate NGS platform.

About New England Biolabs (NEB)

Established in the mid 1970's, New England Biolabs, Inc. leads the industry in the discovery and production of enzymes for molecular biology applications and now offers the largest selection of recombinant and native enzymes for genome research. NEB continues to expand its product offerings into areas related to PCR, cloning, expression and purification, and is focusing on strengthening alliances that enable new technologies to reach key market sectors. New England Biolabs is a privately held company headquartered in Ipswich, MA and has extensive worldwide distribution through a network of exclusive distributors, agents and five subsidiaries located in Canada, China, Germany, Japan and the UK. For more information about New England Biolabs visit (

About Ontario Institute for Cancer Research (OICR)

The Ontario Institute for Cancer Research is a new innovative cancer research centre, moving Ontario to the forefront of discovery and innovation. It is dedicated to research in prevention, early detection, diagnosis and treatment of cancer. OICR is a not-for-profit corporation funded by the Government of Ontario through the Ministry of Research and Innovation. For more information about OICR, visit (

SOURCE New England Biolabs

Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Nanocopoeia Licenses New Polymer-Based Biomaterials Platform From the University of Western Ontario
2. Sparking Growth In Ontarios Biopharmaceutical Industry
3. Senate President Therese Murray, Massachusetts Life Sciences Center, and Howard Hughes Medical Institute Join Marine Biological Laboratory (MBL) for Loeb Laboratory Groundbreaking Ceremony
4. CELLECTA, INC. to Develop New Approach for Cancer Gene Discovery in Partnership with Roswell Park Cancer Institute and Health Research, Inc.
5. HUYA Bioscience Establishes First-Look Agreement With Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences (GIBH)
6. SRA International Wins $16 Million Contract from Cancer Prevention and Research Institute of Texas
7. Pacific Health Research Institute Awarded $2.8 Million in Research Funding
8. Pacific Health Research Institute Awarded $2.8 Million in Research Funding
9. Bayer CropScience Announces Investment of $25 Million for Institute Site
10. Korea Institute of Toxicology Implementing Xybion's Pristima™
11. K-States Biosecurity Research Institute Gives Researchers the Tools Needed to Study Diseases That Cost Pig Producers Hundreds of Millions of Dollars Each Year
Post Your Comments:
(Date:6/23/2016)... 23, 2016   EpiBiome , a precision microbiome ... in debt financing from Silicon Valley Bank (SVB). The ... to advance its drug development efforts, as well as ... "SVB has been an incredible strategic partner to ... traditional bank would provide," said Dr. Aeron Tynes ...
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
(Date:6/23/2016)... ... 23, 2016 , ... ClinCapture, the only free validated electronic ... showcase its product’s latest features from June 26 to June 30, 2016 for ... Disrupting Clinical Trials in The Cloud during the conference. DIA (Drug Information ...
(Date:6/23/2016)... adds 2016 global ... pharmaceuticals section with historic and forecast data along ... Complete report on the Cell Culture ... companies and supported with 261 tables and figures ... The Global Cell Culture Media Industry ...
Breaking Biology Technology:
(Date:4/13/2016)... physicians supporting Medicaid patients in Central Florida ... telehealth thanks to a new partnership with higi.   ... can routinely track key health measurements, such as blood ... they opt in, share them with IMPOWER clinicians through ... location at no cost. By leveraging this data, IMPOWER ...
(Date:3/29/2016)... LegacyXChange, Inc. (OTC: LEGX ... Protect are pleased to announce our successful effort to ... of writing instruments, ensuring athletes signatures against counterfeiting and ... athletes on LegacyXChange will be assured of ongoing proof ... Bill Bollander , CEO states, "By inserting ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):